Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 29, 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific personnel transactions rather than a financial performance report.
Material Changes
The filing discloses a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) for a connected person:
- Connected Person: Dr K Slaoui (Connected person of Dr M Slaoui).
- Transaction Date: September 26, 2014.
- Number of ADSs: 5.
- Price per ADS: $46.59.
- Cause: Revaluation of the cash element of the notional investment held within the GSK 401K plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction noted above.
Investor Verification Checklist
- Verify the identity of Dr K Slaoui and their relationship to Dr M Slaoui.
- Confirm the impact of the 401K plan revaluation on the notional allocation of ADSs.
- Review the price of $46.59 per ADS against market prices on September 26, 2014.
- Check for any other concurrent filings regarding executive compensation or insider trading.